Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Ford

Showing results (11-20 of 508) with videos related to

Pageof 51
Sort By:
BMJ (Clinical Research Ed.)|December 2, 2010
Academic sponsorship. Time to treat as independentTom Macdonald, Chris Hawkey, Ian Ford
The New England Journal of Medicine|December 18, 2014
Ivabradine in stable coronary artery diseaseKim Fox, Ian Ford, Roberto Ferrari
Drugs|March 6, 2007
Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trialWitold Ruzyllo, Michal Tendera, Ian Ford, et al.
Circulation|February 12, 2016
Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention StudyIan Ford, Heather Murray, Colin McCowan, et al.
Lancet (London, England)|September 2, 2008
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trialKim Fox, Ian Ford, P Gabriel Steg, et al.
American Heart Journal|October 31, 2006
Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) studyKim Fox, Roberto Ferrari, Michal Tendera, et al.
Blood Pressure|January 23, 2016
Importance of sustained and "tight" blood pressure control in patients with high cardiovascular riskPeter A Meredith, Suzanne M Lloyd, Ian Ford, et al.
Blood Pressure|January 23, 2016
Prognostic importance of pretreatment and on-treatment blood pressure: Further analysis of the ACTION database and the effect of nifedipine gastrointestinal therapeutic systemHenry L Elliott, Suzanne M Lloyd, Ian Ford, et al.
The American Journal of Cardiology|October 3, 2002
Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS)Leanne Streja, Chris J Packard, James Shepherd, et al.
Kardiologiia|October 4, 2013
[Coronary artery disease in Russia: todays reality evidenced by the international CLARIFY registry]S A Shal'nova, R G Oganov, Ph G Steg, et al.
Pageof 51

Showing results (11-20 of 508) with videos related to

Sort By:
Pageof 51
BMJ (Clinical Research Ed.)|December 2, 2010
Academic sponsorship. Time to treat as independentTom Macdonald, Chris Hawkey, Ian Ford
The New England Journal of Medicine|December 18, 2014
Ivabradine in stable coronary artery diseaseKim Fox, Ian Ford, Roberto Ferrari
Drugs|March 6, 2007
Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trialWitold Ruzyllo, Michal Tendera, Ian Ford, et al.
Circulation|February 12, 2016
Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention StudyIan Ford, Heather Murray, Colin McCowan, et al.
Lancet (London, England)|September 2, 2008
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trialKim Fox, Ian Ford, P Gabriel Steg, et al.
American Heart Journal|October 31, 2006
Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) studyKim Fox, Roberto Ferrari, Michal Tendera, et al.
Blood Pressure|January 23, 2016
Importance of sustained and "tight" blood pressure control in patients with high cardiovascular riskPeter A Meredith, Suzanne M Lloyd, Ian Ford, et al.
Blood Pressure|January 23, 2016
Prognostic importance of pretreatment and on-treatment blood pressure: Further analysis of the ACTION database and the effect of nifedipine gastrointestinal therapeutic systemHenry L Elliott, Suzanne M Lloyd, Ian Ford, et al.
The American Journal of Cardiology|October 3, 2002
Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS)Leanne Streja, Chris J Packard, James Shepherd, et al.
Kardiologiia|October 4, 2013
[Coronary artery disease in Russia: todays reality evidenced by the international CLARIFY registry]S A Shal'nova, R G Oganov, Ph G Steg, et al.
Pageof 51